ArticlePloS one2025
The impact of dose and discontinuation timing of preoperative ACE inhibitors on survival outcomes in cardiac surgery: A MIMIC-IV database analysis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostoperative mortality following cardiac surgery remains high, highlighting the need to optimize perioperative medication strategies. Angiotensin-converting enzyme inhibitors (ACEIs) exert cardioprotective effects; however, the impact of their preoperative use on postoperative outcomes remains uncertain. This study evaluated the association between preoperative ACEI use and postoperative outcomes in cardiac surgery patients using a large dataset.
methodsThis retrospective cohort study included patients from the MIMIC-IV database, grouped by preoperative ACEI use and non-ACEI use. Primary outcomes included in-hospital mortality; secondary outcomes included 30-day, 90-day, and 1-year mortality. Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association between ACEI use and postoperative mortality. Subgroup analyses were used to assess discontinuation timing and lisinopril doses. Propensity score matching was used to control for confounders.
resultsOf 17,175 patients, 1,516 used ACEIs preoperatively. Cox modeling showed that preoperative ACEI use was significantly associated with reduced in-hospital mortality (HR 0.615; 95% CI 0.506-0.747; p < 0.001) and 30- and 90-day mortality (p < 0.05). Subgroup suggested a significant association between ACEI use and lower mortality in patients without malignancy. Continuing ACEIs on the day of surgery was associated with reduced in-hospital mortality, whereas discontinuation was associated with an attenuation of this beneficial association. A medium lisinopril dose (10-20 mg) was associated with the most consistent reduction in postoperative mortality. Results persisted after propensity score matching (p < 0.001).
conclusionsContinuing preoperative ACEI use on the day of surgery was associated with significantly reduced postoperative mortality. Medium-dose lisinopril was associated with the most consistent reduction in postoperative mortality, although patients with malignancy may require individualized assessment. These findings suggest that evidence-based perioperative ACEI management may be beneficial and warrant further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.